guest ::
| Home > Publications database > Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). > print |
| Home > Publications database > Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). > print |
| 001 | 167470 | ||
| 005 | 20240229133541.0 | ||
| 024 | 7 | _ | |a pmid:33585982 |2 pmid |
| 024 | 7 | _ | |a 0001-6322 |2 ISSN |
| 024 | 7 | _ | |a 1432-0533 |2 ISSN |
| 024 | 7 | _ | |a doi: 10.1007/s00401-021-02276-5. |2 doi |
| 024 | 7 | _ | |a doi: 10.1007/s00401-021-02276-5. |2 doi |
| 037 | _ | _ | |a DKFZ-2021-00373 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Fisher, Michael J |b 0 |
| 245 | _ | _ | |a Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). |
| 260 | _ | _ | |a Heidelberg |c 2021 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1641312545_12534 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Apr;141(4):605-617 / #EA:B360#LA:B062# |
| 520 | _ | _ | |a Low-grade gliomas (LGGs) are the most common childhood brain tumor in the general population and in individuals with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome. Surgical biopsy is rarely performed prior to treatment in the setting of NF1, resulting in a paucity of tumor genomic information. To define the molecular landscape of NF1-associated LGGs (NF1-LGG), we integrated clinical data, histological diagnoses, and multi-level genetic/genomic analyses on 70 individuals from 25 centers worldwide. Whereas, most tumors harbored bi-allelic NF1 inactivation as the only genetic abnormality, 11% had additional mutations. Moreover, tumors classified as non-pilocytic astrocytoma based on DNA methylation analysis were significantly more likely to harbor these additional mutations. The most common secondary alteration was FGFR1 mutation, which conferred an additional growth advantage in multiple complementary experimental murine Nf1 models. Taken together, this comprehensive characterization has important implications for the management of children with NF1-LGG, distinct from their sporadic counterparts. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to PubMed, |
| 650 | _ | 7 | |a FGFR1 |2 Other |
| 650 | _ | 7 | |a Methylation |2 Other |
| 650 | _ | 7 | |a Neurofibromatosis |2 Other |
| 650 | _ | 7 | |a Pediatric brain tumor |2 Other |
| 650 | _ | 7 | |a Pilocytic astrocytoma |2 Other |
| 700 | 1 | _ | |a Jones, David T W |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 1 |e First author |
| 700 | 1 | _ | |a Li, Yimei |b 2 |
| 700 | 1 | _ | |a Guo, Xiaofan |b 3 |
| 700 | 1 | _ | |a Sonawane, Poonam S |b 4 |
| 700 | 1 | _ | |a Waanders, Angela J |b 5 |
| 700 | 1 | _ | |a Phillips, Joanna J |b 6 |
| 700 | 1 | _ | |a Weiss, William A |b 7 |
| 700 | 1 | _ | |a Resnick, Adam C |b 8 |
| 700 | 1 | _ | |a Gosline, Sara |b 9 |
| 700 | 1 | _ | |a Banerjee, Jineta |b 10 |
| 700 | 1 | _ | |a Guinney, Justin |b 11 |
| 700 | 1 | _ | |a Gnekow, Astrid |b 12 |
| 700 | 1 | _ | |a Kandels, Daniela |b 13 |
| 700 | 1 | _ | |a Foreman, Nicholas K |b 14 |
| 700 | 1 | _ | |a Korshunov, Andrey |b 15 |
| 700 | 1 | _ | |a Ryzhova, Marina |b 16 |
| 700 | 1 | _ | |a Massimi, Luca |b 17 |
| 700 | 1 | _ | |a Gururangan, Sri |b 18 |
| 700 | 1 | _ | |a Kieran, Mark W |b 19 |
| 700 | 1 | _ | |a Wang, Zhihong |b 20 |
| 700 | 1 | _ | |a Fouladi, Maryam |b 21 |
| 700 | 1 | _ | |a Sato, Mariko |b 22 |
| 700 | 1 | _ | |a Øra, Ingrid |b 23 |
| 700 | 1 | _ | |a Holm, Stefan |b 24 |
| 700 | 1 | _ | |a Markham, Stephen J |b 25 |
| 700 | 1 | _ | |a Beck, Pengbo |0 P:(DE-He78)b8f2b74d0482aed61472c7065dc1ed56 |b 26 |u dkfz |
| 700 | 1 | _ | |a Jäger, Natalie |0 P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3 |b 27 |u dkfz |
| 700 | 1 | _ | |a Wittmann, Andrea |0 P:(DE-He78)adf0bc22f6c87d09ddb939645a7870ed |b 28 |u dkfz |
| 700 | 1 | _ | |a Sommerkamp, Alexander C |0 P:(DE-He78)193d882d3418c5d0ffbb210947510711 |b 29 |u dkfz |
| 700 | 1 | _ | |a Sahm, Felix |b 30 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 31 |e Last author |u dkfz |
| 700 | 1 | _ | |a Gutmann, David H |0 0000-0002-3127-5045 |b 32 |
| 773 | _ | _ | |a 10.1007/s00401-021-02276-5. |0 PERI:(DE-600)1458410-4 |n 4 |p 605-617 |t Acta neuropathologica |v 141 |y 2021 |x 0001-6322 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:167470 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)b8f2b74d0482aed61472c7065dc1ed56 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)adf0bc22f6c87d09ddb939645a7870ed |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 29 |6 P:(DE-He78)193d882d3418c5d0ffbb210947510711 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 31 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-08-23 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2020-08-23 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-08-23 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-08-23 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACTA NEUROPATHOL : 2018 |d 2020-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2020-08-23 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2020-08-23 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b ACTA NEUROPATHOL : 2018 |d 2020-08-23 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pediatric Glioma |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|